Praxis Precision Medicines (PRAX) EBIT (2019 - 2026)
Praxis Precision Medicines (PRAX) posted quarterly EBIT of -$105.9 million for Q1 2026, down 41.66% year-over-year from -$181.5 million in Q1 2025, and down 9.08% quarter-over-quarter from -$97.0 million in Q4 2025.
Praxis Precision Medicines (PRAX) EBIT (2019 - 2026) Analysis & Trends
Praxis Precision Medicines' EBIT history runs 8 years deep, the most recent figure standing at -$105.9 million for Q1 2026.
- In Q1 2026, EBIT fell 41.66% year-over-year to -$105.9 million; the TTM figure through Mar 2026 stood at -$357.3 million (down 53.36% YoY), while the FY2025 annual figure was -$326.2 million, down 62.96% from the prior year.
- EBIT for Q1 2026 stood at -$105.9 million, down from -$97.0 million in the prior quarter.
- The five-year high for EBIT was -$25.5 million in Q3 2023, with the low at -$105.9 million in Q1 2026.
- The 5-year median for EBIT is -$56.8 million (2024), against an average of -$57.3 million.
- The sharpest annual moves came in 2022 and 2023: EBIT plunged 151.1% in 2022, then surged 44.67% in 2023.
- Praxis Precision Medicines' EBIT stood at -$41.5 million in 2022, then surged by 32.92% to -$27.8 million in 2023, then slumped by 130.01% to -$64.0 million in 2024, then tumbled by 51.74% to -$97.0 million in 2025, then declined by 9.08% to -$105.9 million in 2026.
- Business Quant data shows PRAX's EBIT at -$105.9 million in Q1 2026, -$97.0 million in Q4 2025, and -$78.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Praxis Precision Medicines | 10.24 Bn | 9.48 Bn | - | -96.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96.90 Mn |
| Mar 31, 2026 | -105.86 Mn |
| Dec 31, 2025 | -97.04 Mn |
| Sep 30, 2025 | -78.36 Mn |
| Jun 30, 2025 | -76.07 Mn |
| Mar 31, 2025 | -74.73 Mn |
| Dec 31, 2024 | -63.96 Mn |
| Sep 30, 2024 | -56.84 Mn |
| Jun 30, 2024 | -37.49 Mn |
| Mar 31, 2024 | -41.89 Mn |
| Dec 31, 2023 | -27.81 Mn |
| Sep 30, 2023 | -25.52 Mn |
| Jun 30, 2023 | -34.96 Mn |
| Mar 31, 2023 | -38.09 Mn |
| Dec 31, 2022 | -41.45 Mn |
| Sep 30, 2022 | -44.29 Mn |
| Jun 30, 2022 | -60.39 Mn |
| Mar 31, 2022 | -68.85 Mn |
| Dec 31, 2021 | -58.66 Mn |
| Sep 30, 2021 | -44.77 Mn |